Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 13/20 | 0.65 |
| ▸ | CNR1 | P21554 | 4/20 | 0.43 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2513154 | 1.00 | AVPR1A (0.65) | AVPR1ACNR1OXTRCNR2F2 | |
| SCHEMBL2514280 | 0.91 | AVPR1A (0.79) | AVPR1ACNR1OXTRCNR2 | |
| SCHEMBL8167559 | 0.90 | AVPR1A (0.62) | AVPR1ACNR1OXTRCNR2 | |
| SCHEMBL2516015 | 0.90 | AVPR1A (0.62) | AVPR1ACNR1OXTRCNR2 | |
| SCHEMBL2518987 | 0.88 | AVPR1A (0.65) | AVPR1ACNR1OXTRCNR2F2 | |
| SCHEMBL2518989 | 0.88 | AVPR1A (0.65) | AVPR1ACNR1OXTRCNR2F2 | |
| SCHEMBL3400283 | 0.87 | AVPR1A (0.80) | AVPR1ACNR1OXTRCNR2 | |
| Hydrochloric Acid SCHEMBL2515454 | 0.86 | AVPR1A (0.78) | AVPR1ACNR1OXTRCNR2 | |
| SCHEMBL2524187 | 0.85 | AVPR1A (0.68) | AVPR1ACNR1OXTRCNR2F2 | |
| SCHEMBL2524189 | 0.85 | AVPR1A (0.68) | AVPR1ACNR1OXTRCNR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125827-B1 | AZASPIRO DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-11-03 | — | — | EP | claimed |
| US-20080161332-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | US | claimed |
| US-8044202-B2 | e.g.1'-[(6-chloro-1H-indol-3-yl)carbonyl]-7H-spiro[pentane[3,4-b]pyridine-5,4'-piperidine]; vasopressin V1a receptor antagonist; antidepressant and anxiolytic agent; dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8039624-B2 | Vasopressin receptor antagonist; antidepressants; anxiolytic agents; dysmemorrhea; hypotensive agents;obsessive complusive disorder; cirrhosis; nephrotic syndrome | HOFFMAN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8034937-B2 | e.g.1'-[(6-chloro-1H-indol-3-yl)carbonyl]-7H-spiro[furo[3,4-b]pyridine-5,4'-piperidine]; vasopressin V1a receptor antagonist; antidepressant and anxiolytic agent; dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2011-10-11 | — | — | US | disclosed |
| EP-2125827-B1 | AZASPIRO DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-11-03 | — | — | EP | disclosed |
| EP-2125827-A1 | AZASPIRO DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-20080281103-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-11-13 | — | — | US | disclosed |
| WO-2008080844-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161333-A1 | AZASPIRO DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161332-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080281103-A1 | AZASPIRO DERIVATIVES | AVPR1A, HTR5A, HTR1A | AVPR1A 1/4885CNR1 31/4885OXTR 22/4885 |
| US-20080161332-A1 | AZASPIRO DERIVATIVES | AVPR1A, HTR5A, HTR1A | AVPR1A 1/4885CNR1 31/4885OXTR 22/4885 |
| US-20080161333-A1 | AZASPIRO DERIVATIVES | AVPR1A, HTR5A, HTR1A | AVPR1A 1/4885CNR1 31/4885OXTR 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.